The conclusion of the conversation is that dying the hair can be an effective method for managing hair loss, particularly for those with diffuse thinning.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
The conversation discusses whether to use finasteride for hair loss, considering its role in inhibiting DHT and 5AR, which can affect brain function and mood. Some users report anxiety and depression from finasteride, while others do not experience these side effects and emphasize the importance of DHT for brain and prostate health.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It highlights the South Korean president's push for public health coverage for hair loss.
The conversation is about the best way to take finasteride for hair loss, questioning whether it should be taken with food or on an empty stomach for optimal results. People are sharing their experiences with taking finasteride alongside meals.
Coffee's effect on hair loss is debated, with some suggesting it may exacerbate hair loss due to vasoconstriction, while others believe it could have positive effects. Topical caffeine might be beneficial, but ingesting it could potentially inhibit vitamin D receptors.
The conversation humorously discusses hair loss treatments, mentioning "oral miraclegro," "topical roundup," "spectracide," "Cow Dung mesotherapy," and "weekly Foot stepping sessions." The user jokingly considers switching to "weed and feed" as a treatment.
A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.
Scalp Botox may help hair loss by relaxing muscles and increasing blood flow, potentially benefiting conditions other than androgenetic alopecia. DHT affects hair follicles differently, causing tension and hair loss in some areas but not others.
Some users report eye issues like blurry vision and dry eyes while using finasteride or dutasteride, though others experience no changes. Concerns about myopia progression are discussed, but no clear link to these medications is established.
User plans to use hair fibers regularly and asks about re-application, consistency, rain protection, and Boldify vs Toppik. Others provide advice and share experiences.
A 30-year-old male is experiencing hair loss and is concerned about his receding hairline, seeking advice on his Norwood scale classification. He is apprehensive about using Minoxidil and finasteride as treatments.
The user reports that using topical Dutasteride has stopped their hair loss, and they are curious about potential side effects and regrowth. They also mention having scalp psoriasis and past SSRI use affecting libido.
The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.
Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.
Dutasteride and finasteride can cause changes in physical appearance, like more feminine features and increased water retention. Users report side effects such as reduced libido, weight gain, and improved skin clarity, while some notice no significant changes.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.
People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
The conversation humorously discusses using a dermaroller for hair growth, with a playful suggestion of using it on the wrist. It includes references to Minoxidil, finasteride, and RU58841 as treatments.
A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.
A 33-year-old male is experiencing thinning at the temples and hairline, with increased shedding over the past year. The user suspects androgenetic alopecia (AGA) despite AI suggesting a maturing hairline.
Gut microbiota significantly influences androgen metabolism, impacting hair loss treatments like finasteride. Probiotics, dietary changes, and fecal microbiota transplants may help manage DHT levels and improve hair health.
User shows hair loss progress from NW4 to NW2.5 in 2.5 months using RU 8.5-9% daily and topical Dut .1% + RU 5% weekly. Discussion includes managing tension in African American hair and representation of different hair types.
The user has been using topical Minoxidil for 8 months and oral Finasteride for 4 months, along with weekly derma rolling, to treat hair loss. They report no side effects and cannot access Dutasteride in their country.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.